Stimulated high serum thyroglobulin with negative whole body imaging do not warrant an aggressive diagnostic and therapeutic approach in differentiated thyroid cancer patients: A follow-up of 5 years or till recurrence.
To study the clinical significance of stimulated high serum thyroglobulin (sTg) and of normal whole body imaging (WBI) in differentiated thyroid cancer (DTC) patients during their first follow-up and in a 5 years follow-up or till recurrence. Sixty four DTC patients were retrospectively studied and were divided into two groups. Group 1, of 35 patients with disease free status on their first follow-up and group 2, of 29 patients with high sTg (>2 μg/mL), but with normal WBI, iodine-131 (¹³¹I) findings. Patients were categorized into low, intermediate and high risk patients based on the ¹³¹I WBS findings. Histology, stage and risk-categories of both groups were statistically correlated. Best sTg cut-off for predicting recurrence was generated by receiver operating characteristic (ROC). Odd ratio for sTg trend was also analyzed for risk of recurrence in group 2. Independent t test was used for progression free survival (PFS) comparison of the two groups. No statistical differences were seen in histology, stage and risk category distributions between the groups. Group 2 patients with high sTg (range 2.5-81 μg/L, mean 20.5 μg/L) on their first follow-up had higher risk of recurrence (odd ratio 4.304) but P value was insignificant (P:0.090). Eighty six per cent of group 2 patients showed decreasing trends and in 62% of group 2 patients, high serum sTg fell to normal. Indeed, decreasing trends of sTg reduced the risk of recurrence (odd ratio 1.3939, P:0.79). Analysis by ROC showed that sTg>11 μg/L was the best cut-off in predicting recurrence with sensitivity 100% and specificity 56%. High sTg was not associated with low PFS, (P:0.232), however patients with increasing sTg had significantly shorter PFS (P<0.005). High sTg with negative ¹³¹I WBS did not warrant an aggressive DTC disease. These patients in their 5 years or till recurrence follow-up showed downward trends of serum sTg, no higher risk or recurrence and no shorter PFS.